Costentin Charlotte
Hôpital Henri-Mondor, unité d'hépatologie, 51, avenue du Maréchal-de-Tassigny, 94000 Créteil, France.
Presse Med. 2017 Apr;46(4):381-385. doi: 10.1016/j.lpm.2016.11.006. Epub 2017 Jan 9.
Hepatocellular carcinoma related mortality is one of the highest among all cancers. Ninety percent of all hepatocellular carcinoma develop in the context of liver cirrhosis. Liver cirrhosis is not recognized prior to the diagnosis of hepatocellular carcinoma in 25 % of the cases, despite the existence of risk factors. Hepatocellular carcinoma is diagnosed within a surveillance program in less than 25 % of the cases. Ultrasound screening for hepatocellular carcinoma every 6 months increases chances to diagnose HCC at an early stage amenable to curative treatment, and increases survival. Interval greater than 7months between ultrasound imaging has a significant negative impact on survival. All patients diagnosed with cirrhosis have to perform an ultrasound screening for hepatocellular carcinoma and comply with the six months rule.
肝细胞癌相关死亡率在所有癌症中位居前列。所有肝细胞癌病例中有90%是在肝硬化背景下发生的。尽管存在风险因素,但在25%的病例中,肝细胞癌诊断前未识别出肝硬化。不到25%的肝细胞癌病例是在监测计划中确诊的。每6个月进行一次肝细胞癌超声筛查可增加在适合根治性治疗的早期阶段诊断出肝癌的机会,并提高生存率。超声成像间隔超过7个月对生存率有显著负面影响。所有被诊断为肝硬化的患者都必须进行肝细胞癌超声筛查并遵守6个月规则。